IDNA:NYE-iShares Genomics Immunology and Healthcare ETF (USD)

ETF | Health |

Last Closing

USD 20.2

Change

+0.12 (+0.60)%

Market Cap

USD 0.10B

Volume

0.02M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-27 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

+1.82 (+1.40%)

USD 33.98B
FHLC Fidelity® MSCI Health Care In..

+0.86 (+1.40%)

USD 2.37B
FXH First Trust Health Care AlphaD..

+2.08 (+2.09%)

USD 0.90B
XHE SPDR® S&P Health Care Equipme..

+2.32 (+2.91%)

USD 0.17B
XHS SPDR® S&P Health Care Service..

+1.51 (+1.58%)

USD 0.09B
SBIO ALPS Medical Breakthroughs ETF

-0.22 (-0.77%)

USD 0.08B
HTEC Robo Global® Healthcare Techn..

+0.62 (+2.34%)

USD 0.04B
BBP Virtus LifeSci Biotech Product..

+0.20 (+0.36%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

-0.37 (-2.05%)

USD 0.01B
IHF iShares U.S. Healthcare Provid..

+0.44 (+0.95%)

N/A

ETFs Containing IDNA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -10.74% 19% F 17% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -10.74% 19% F 17% F
Trailing 12 Months  
Capital Gain -14.33% 10% F 18% F
Dividend Return 0.47% 44% F 7% C-
Total Return -13.86% 10% F 17% F
Trailing 5 Years  
Capital Gain -42.87% 10% F 10% F
Dividend Return 2.59% 53% F 5% F
Total Return -40.29% 10% F 8% B-
Average Annual (5 Year Horizon)  
Capital Gain -11.21% 5% F 6% D-
Dividend Return -10.64% 5% F 6% D-
Total Return 0.58% 53% F 14% F
Risk Return Profile  
Volatility (Standard Deviation) 24.34% 14% F 39% F
Risk Adjusted Return -43.70% 5% F 6% D-
Market Capitalization 0.10B 60% D- 27% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.